|
Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial. |
|
|
|
|
|
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Roche Pharma AG |
Speakers' Bureau - Bristol-Myers Squibb; Roche Pharma AG |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Sotio |
|
|
|
|
|
Stock and Other Ownership Interests - Sotio |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
|
Patents, Royalties, Other Intellectual Property - Sotio |
|
|
Consulting or Advisory Role - Beckman Coulter; Daiichi Sankyo; Sotio |
Travel, Accommodations, Expenses - Daiichi Sankyo; Sotio |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |